Clinical trial
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
NCT00005027 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00005027 |
|---|---|
| Title | Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer |
| Official title | A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | becatecarin |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Aug 8, 2003 |
| Last update posted | Apr 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: